ERBB2 and breast cancer: The PAM50 subtyping system, which can further subdivide all breast cancers into Luminal A, Luminal B, Her2, and Basal subtype based on their gene expression features or generally ER/PR and Her2 immuno-staining [19, 20], was widely employed on clinic.